Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab with Chemotherapy and Atezolizumab in Transformed Small Cell Lung Cancer
NCT06830694Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC). Started May 2025; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06830694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830694.